Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Acetic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 15/20 | 0.60 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | PDE4A | P27815 | 1/20 | 0.45 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.45 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.45 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | NEK2 | P51955 | 1/20 | 0.45 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.45 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13089760 | 0.95 | MET (0.61) | METHDAC1MEN1KMT2ACHEK1 | |
| Acetic Acid SCHEMBL27930460 | 0.91 | MET (0.49) | METHDAC1MEN1KMT2APDE4A | |
| Acetic Acid SCHEMBL1951550 | 0.91 | MET (0.49) | METHDAC1MEN1KMT2APDE4A | |
| SCHEMBL4130448 | 0.87 | MET (0.69) | METHDAC1MEN1KMT2ACHEK1 | |
| SCHEMBL1302552 | 0.86 | MET (0.64) | METHDAC1MEN1KMT2ACHEK1 | |
| SCHEMBL3632471 | 0.85 | MET (0.50) | METHDAC1MEN1KMT2APDE4A | |
| SCHEMBL3053136 | 0.84 | MET (0.61) | METHDAC1MEN1KMT2ACHEK1 | |
| Acetic Acid SCHEMBL3092222 | 0.83 | MET (0.58) | METHDAC1 | |
| SCHEMBL3062465 | 0.83 | MET (0.64) | METHDAC1 | |
| SCHEMBL13089759 | 0.83 | MET (0.68) | METMEN1KMT2ACHEK1NEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2754660-B1 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-11-02 | — | — | EP | disclosed |
| US-9284300-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2016-03-15 | — | — | US | disclosed |
| US-9221806-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2015-01-08 | — | — | US | disclosed |
| US-8927540-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| US-8921357-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2014-12-30 | — | — | US | disclosed |
| EP-2164843-B1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2014-10-29 | — | — | EP | disclosed |
| EP-2049531-B1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-09-24 | — | — | EP | disclosed |
| US-8580781-B2 | Pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2013-11-12 | — | — | US | disclosed |
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-07-18 | — | — | US | disclosed |
| US-20130131037-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2013-05-23 | — | — | US | disclosed |
| US-8435981-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-05-07 | — | — | US | disclosed |
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | disclosed |
| EP-2164843-A1 | PYRIDAZINONE DERIVATES | Merck Patent GmbH (DE) | 2010-03-24 | — | — | EP | disclosed |
| EP-2049531-A2 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | Merck Patent GmbH (DE) | 2009-04-22 | — | — | EP | disclosed |
| WO-2009006959-A1 | PYRIDAZINONE DERIVATES | MERCK PATENT GMBH (DE) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008017361-A2 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184261-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885HDAC1 1144/4885MEN1 164/4885 |
| US-20130131037-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | RET, MET, ERBB2 | MET 2/4885HDAC1 854/4885MEN1 157/4885 |
| US-20130184260-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885HDAC1 1182/4885MEN1 173/4885 |
| US-20150011534-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885HDAC1 1182/4885MEN1 173/4885 |
| US-20100234354-A1 | PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885HDAC1 1320/4885MEN1 221/4885 |
| US-20100261697-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MET, RET, ERBB2 | MET 1/4885HDAC1 745/4885MEN1 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.